Isofol Medical
2.01 SEK -20.08%2 investors are following this company
Isofol Medical is a biotechnology company. The company conducts research and development in the fields of oncology. The company develops cancer drugs and drug candidates that are primarily intended for the treatment of colorectal cancer (CRC), one of the most common forms of cancer. In addition to the main activities, the companies also develop so-called rescue treatment after high-dose treatment with the cytotoxic methotrexate in osteosarcoma (bone cancer).
Revenue
720K
EBIT %
-5,788.89 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ISOFOL
Daily low / high price
1.99 / 2.39
SEK
Market cap
324.65M SEK
Turnover
14.34M SEK
Volume
6.8M
Latest videos
Financial calendar
Interim report
2024-08-21
Interim report
2024-11-12
Annual report
2025-02-19
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 10.1 % | 10.1 % |
Christian Haglund | 4.7 % | 4.7 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Isofol announces a post hoc per-protocol analysis of the AGENT study, further supporting arfolitixorin’s continued clinical development
Isofols Chief Financial Officer lämnar bolaget
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Isofol's Chief Financial Officer to leave the company
Isofol och Charité har tecknat ett samarbetsavtal om vidare klinisk utveckling av arfolitixorin
Isofol and Charité sign collaboration agreement on further clinical development of arfolitixorin
Kommuniké från årsstämma i Isofol Medical AB (publ) den 8 maj 2024
Bulletin from annual general meeting in Isofol Medical AB (publ) held on May 8, 2024
Isofol Medical AB (publ) publicerar delårsrapport, januari – mars 2024
Isofol Medical AB (publ) publishes interim report, January–March 2024
Isofol Medical AB (publ) offentliggör årsredovisning och bolagsstyrningsrapport för 2023
Isofol Medical AB (publ) publishes annual report and corporate governance report for 2023
Kallelse till årsstämma den 8 maj 2024 i Isofol Medical AB (publ)
Notice to attend the Annual General Meeting held on May 8, 2024 in Isofol Medical AB (publ)
Finansinspektionen: Flaggningsmeddelande i Isofol Medical AB (publ)
![Isofol Medical, Webcast, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/6ce8aa64-09da-4a52-b078-af6fe2f5323e.png)